Diabetes Device

NEW ORLEANS — In this video exclusive, Osagie Ebekozien, MD, MPH, CPHQ, describes recent findings from T1D Exchange research on inequities in type 1 diabetes care.

NEW ORLEANS — Adults and children with type 1 diabetes who used an insulin-only bionic pancreas had reduced HbA1c without increasing hypoglycemia and other improved metrics compared with standard of care, researchers reported.

NEW ORLEANS — An intervention program powered by artificial intelligence and data collected by sensors was linked to a type 2 diabetes remission rate of more than 80%, according to a presenter.

NEW ORLEANS— In part one of this video exclusive, James R. Gavin III, MD, PhD, talks with Anne L. Peters, MD, about using technology in underserved populations to close the diabetes treatment gap.

The FDA has cleared a next-generation integrated continuous glucose monitor for people with diabetes aged 4 years and older, according to a press release from Abbott.

A novel extended-wear insulin infusion set was usable for up to 7 days for most adults with type 1 diabetes, with no change in glycemic control and few adverse events, according to findings published in Diabetes Technology & Therapeutics.

CHICAGO — In this video, Rajesh K. Garg, MD, the director of the Comprehensive Diabetes Center at the University of Miami Miller School of Medicine, discusses three evolving areas in diabetes management: glucose goals, treatment and devices.

Black adolescents with type 1 diabetes and their parents believe fear, lack of exposure and mistrust of the medical community are some of the reasons racial disparities exist with diabetes device use, according to study findings.

The FDA has approved extending the use of an implantable continuous glucose monitoring sensor for up to 6 months for adults with diabetes, according to a company press release.

This year marks the 20th anniversary of Endocrine Today. In the 2 decades since Endocrine Today was launched, the field of diabetes has undergone immense change.